AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

INTELLIGENT ULTRASOUND GROUP PLC

Director's Dealing May 6, 2020

7714_dirs_2020-05-06_7a773220-ce79-4f87-8303-300c0e9bef03.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1064M

Intelligent Ultrasound Group PLC

06 May 2020

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company")

Director Dealings

Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, announces that further to the Company's announcements on 17 April 2020 and 4 May 2020, certain Directors have, following Admission today, acquired a total of 409,523 Ordinary Shares in the Company via the Placing, as detailed below:

Name Title Number of Existing Ordinary Shares# Number of Placing Shares subscribed for# Value of Placing Shares subscribed for# Resulting shareholding following subscription # Percentage of enlarged share capital following subscription#
Stuart Gall Chief Executive Officer 828,236 95,238 £10,000 923,474 0.34%
Helen Jones Chief Financial Officer 0 95,238 £10,000 95,238 0.04%
Nicholas Sleep Chief Technology Officer 326,471 95,238 £10,000 421,709 0.16%
Ian Whittaker Chief Operating Officer 374,982 76,190 £8,000 451,172 0.17%
Nick Avis Non-Executive Director 225,000 47,619 £5,000 272,619 0.10%

The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 17 April 2020.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1.     Stuart Gall

2.     Helen Jones

3.     Nicholas Sleep

4.     Ian Whittaker

5.     Nick Avis

2

Reason for the notification

a)

Position/status

1.     Chief Executive Officer       

2.     Chief Finance Officer          

3.     Chief Technology Officer

4.     Chief Operating Officer

5.     Non-Executive Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intelligent Ultrasound Group plc

b)

LEI

213800K4ZVWL4ZYQAZ70

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB00BN791Q39

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
1.     10.5  pence

2.     10.5  pence

3.     10.5  pence

4.     10.5  pence

5.     10.5  pence
1.     95,238

2.     95,238

3.     95,238

4.     76,190

5.     47,619

d)

Aggregated information

- Aggregated volume

- Price

N/A - single transaction

e)

Date of the transaction

6 May 2020

f)

Place of the transaction

London Stock Exchange, XLON

Enquiries:

Intelligent Ultrasound Group plc www.intelligentultrasound.com
Stuart Gall, CEO

Helen Jones, CFO
Tel: +44 (0)29 2075 6534
Cenkos Securities plc Tel:  +44 (0)20 7397 8900
Giles Balleny (Nominated Adviser)
Michael Johnson/Julian Morse (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy/Paul McManus Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.

Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:

Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and  AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.

www.intelligentultrasound.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHFZGGKRVZGGZG

Talk to a Data Expert

Have a question? We'll get back to you promptly.